Home > PJ (current issue) > News / News Centre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 277 No 7429 p660
2 December 2006

This article
Reprint   Photocopy

  Acrobat Reader


News summary


Antibiotics more beneficial in bilateral otitis media

Antibiotics are beneficial for relieving pain and fever in children aged under two years with acute otitis media in both ears or for children of any age with acute otitis media and otorrhoea (discharge from the ear), the authors of a study published in The Lancet conclude (2006;368:1429). For most other children with mild disease a watch and wait policy seems justified, they say.

The meta-analysis combined data from six trials involving 1,643 children aged six months to 12 years. The primary outcome was persistence of otitis media with pain or fever, or both, at three to seven days.

In children under two years old with bilateral otitis media, four would need to be treated to prevent an extended course of the disease in one child. In children older than two years with bilateral infection the number needed to treat would be nine. In children with unilateral infection the numbers needed to treat would be 20 and 15, respectively. The researchers also found that children with otorrhoea were more likely to benefit from antibiotics.

The researchers postulate that in children younger than two years with bilateral otitis media and in those with otorrhoea, the infection is more often bacterial than viral.

Antihistamines and decongestants Antihistamines and decongestants should not be used either alone or in combination to treat acute otitis media with discharge in children, according to a recent Cochrane review. The reviewers analysed 15 trials involving 1,516 children and found no statistical or clinical benefit for any of the interventions or outcomes studied. In addition, in the six studies that examined side effects, treated subjects experienced 11 per cent more side effects than untreated subjects. This means that for every nine children treated, one will be harmed and none will benefit.

Back to Top


©The Pharmaceutical Journal